Currently, several pharmaceutical drugs targeting the key players of this pathway (i.e., Ang2, both Ang2 and VEGF, both Ang1 and Ang2, VE-PTP or TIE2) are under clinical development, especially for the treatment of human cancer or diabetic retinal diseases [17,18]. This evidence concerns the gene ANGPT1 and cancer.